MARKET

RGLS

RGLS

Regulus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7041
+0.0107
+1.54%
Closed 16:00 10/17 EDT
OPEN
0.7001
PREV CLOSE
0.6934
HIGH
0.7400
LOW
0.6728
VOLUME
83.57K
TURNOVER
--
52 WEEK HIGH
3.140
52 WEEK LOW
0.5026
MARKET CAP
14.66M
P/E (TTM)
-0.2545
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of RGLS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

RGLS News

  • Regulus Therapeutics Presents Preclinical Data Identifying RGLS4326 as a Potential Disease-Modifying Treatment for Autosomal Dominant Polycystic Kidney Disease at OTS Annual Meeting
  • PR Newswire.23h ago
  • Some Regulus Therapeutics (NASDAQ:RGLS) Shareholders Have Copped A 99% Share Price Wipe Out
  • Simply Wall St..09/20 18:30
  • Regulus Therapeutics Announces Publication in Nature Communications Identifying RGLS4326 as a Potential Promising Treatment for ADPKD
  • PR Newswire.09/12 13:00
  • Benzinga's Top Upgrades, Downgrades For September 6, 2019
  • Benzinga.09/06 13:37

More

Industry

Biotechnology & Medical Research
+1.00%
Pharmaceuticals & Medical Research
+0.65%

Hot Stocks

Name
Price
%Change

About RGLS

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company's Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.
More

Webull offers Regulus Therapeutics Inc (RGLS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.